This finding suggests that luminal tumour cells expressing activated phospho-PR species confer increased aggressiveness, the clinical implication being that luminal B-type breast cancers (i.e. scored as PR-low/null by IHC) may contain activated PRs. This evidence concerns the gene WNK3 and breast carcinoma.